Replies to post #424117 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

I find it mindboggling that people downplay an AD P2b/3 trial that met all endpoints

From my perspective, I don't know that it is "downplaying" so much as it is a lack of confidence that the trial is going to result in near-term approval. It's just so hard to reconcile the 48% loss in stock price since mid November 2022 with a trial "that met all endpoints" coupled with no additional data from the company that said it was coming. It will be remarkable if a few WGT iHub posters wind up right about an upcoming near-term regulatory approval, but I sure hope they are because I have a lot of $ wrapped up in AVXL.